Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Psychooncology ; 23(8): 862-9, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24443031

ABSTRACT

BACKGROUND: Up to three-quarters of individuals who undergo cancer genetic counseling and testing report psychosocial problems specifically related to that setting. The objectives of this study were to develop and evaluate the screening properties of a questionnaire designed to assess specific psychosocial problems related to cancer genetic counseling. METHODS: We adopted the European Organisation for Research and Treatment of Cancer Quality of Life Group guidelines to develop the Psychosocial Aspects of Hereditary Cancer (PAHC) questionnaire, a 26-item questionnaire organized into six problem domains: genetics, practical issues, family, living with cancer, emotions, and children. The Distress Thermometer and a question per domain on the perceived need for extra psychosocial services were included as well. We administered the questionnaire and the Hospital Anxiety and Depression Scale to 127 counselees at the time of genetic counseling and 3 weeks after DNA test disclosure. As a gold standard to evaluate the screening properties of the questionnaire, participants underwent a semi-structured interview with an experienced social worker who assessed the presence and severity of problems per domain. RESULTS: A cutoff score representing responses of 'quite a bit' or 'very much' to one or more items within a given problem domain yielded moderate to high sensitivity across domains. A cutoff of 4 on the Distress Thermometer yielded high sensitivity. The questions regarding the perceived need for extra psychosocial services yielded high specificity and negative predictive values. CONCLUSION: The Psychosocial Aspects of Hereditary Cancer questionnaire in combination with the Distress Thermometer can be used as a first-line screener for psychosocial problems within the cancer genetic counseling setting.


Subject(s)
Anxiety/diagnosis , Depression/diagnosis , Genetic Counseling/psychology , Genetic Predisposition to Disease/psychology , Neoplastic Syndromes, Hereditary/psychology , Stress, Psychological/diagnosis , Adolescent , Adult , Aged , Anxiety/psychology , Depression/psychology , Female , Genetic Testing , Humans , Male , Mass Screening , Middle Aged , Neoplastic Syndromes, Hereditary/genetics , Netherlands , Stress, Psychological/psychology , Surveys and Questionnaires , Young Adult
2.
Psychooncology ; 21(5): 479-87, 2012 May.
Article in English | MEDLINE | ID: mdl-21351188

ABSTRACT

OBJECTIVE: This study aimed to evaluate self-reported cognitive functioning of postmenopausal breast cancer patients before and during endocrine treatment compared with healthy female controls, and to investigate associations between self-reported cognitive functioning, cognitive test performance and anxiety/depression, fatigue, and menopausal complaints. METHODS: Self-reported cognitive functioning, anxiety/depression, fatigue, menopausal complaints, and cognitive tests performance were assessed before (T1) and after 1 year (T2) of adjuvant endocrine treatment in postmenopausal chemotherapy-naïve breast cancer patients. Self-reported cognitive functioning was assessed by the cognitive failures questionnaire and interview questions concerning cognitive complaints. Patients participated in the TEAM-trial, a prospective randomized study investigating tamoxifen versus exemestane as adjuvant therapy for hormone-sensitive breast cancer. Identical information was obtained from healthy postmenopausal volunteers. RESULTS: Two measures for self-reported cognitive functioning provided the distinctive results. At T1 and T2, healthy controls reported a higher frequency of cognitive failures than patients; change over time did not differ between groups. The prevalence of cognitive complaints did not differ between the groups at T1, but change over time regarding attention/concentration complaints differed between groups, due to an increased prevalence in tamoxifen users. Self-reported cognitive functioning showed moderate associations with anxiety/depression, fatigue, and menopausal complaints. Cognitive test performance was not associated with self-reported cognitive functioning, but weakly with anxiety/depression and fatigue. CONCLUSION: Adjuvant therapy with tamoxifen and exemestane did not influence the self-reported frequency of cognitive failures. Increased attention/concentration complaints were observed in tamoxifen users, but not in exemestane users. This latter finding should be confirmed with better validated instruments.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/psychology , Cognition , Postmenopause/psychology , Aged , Aged, 80 and over , Androstadienes/therapeutic use , Anxiety , Case-Control Studies , Chemotherapy, Adjuvant/psychology , Cognition Disorders , Depression , Female , Humans , Middle Aged , Neuropsychological Tests , Prospective Studies , Randomized Controlled Trials as Topic , Self Report , Surveys and Questionnaires , Tamoxifen/therapeutic use
3.
Psychooncology ; 20(6): 631-8, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21384469

ABSTRACT

OBJECTIVE: Li Fraumeni syndrome (LFS) and Von Hippel-Lindau disease (VHL) are two rare hereditary tumor syndromes, characterized by a high risk of developing multiple tumors at various sites and ages for which preventive and treatment options are limited. For partners, it may be difficult to deal with the on-going threat of tumors in both their spouse and children. Therefore, this study aims to evaluate the prevalence of and factors associated with psychological distress among partners of individuals with or at high risk of LFS or VHL. METHODS: As part of a nationwide, cross-sectional study, partners of individuals diagnosed with or at high risk of LFS or VHL were invited to complete a self-report questionnaire assessing distress, worries, and health-related quality of life. RESULTS: Fifty-five (58%) of those high-risk individuals with a partner consented to having their partner approached for the study. In total, 50 partners (91%) completed the questionnaire, of whom 28% reported clinically relevant levels of syndrome-related distress. Levels of distress and worries of the partners and their high-risk spouse were significantly correlated. Younger age and a lack of social support were also associated significantly with heightened levels of distress and worries. The majority of partners (76%) believed that professional psychosocial support should be routinely offered to them. CONCLUSIONS: Approximately one-quarter of the partners exhibit clinically relevant levels of distress that warrant psychological support. The distress levels of the 'patient' could potentially be used to identify partners at risk of developing clinically relevant levels of distress.


Subject(s)
Adaptation, Psychological , Adjustment Disorders/psychology , Anxiety Disorders/psychology , Depressive Disorder/diagnosis , Genetic Predisposition to Disease/psychology , Li-Fraumeni Syndrome/diagnosis , Li-Fraumeni Syndrome/psychology , Spouses/psychology , von Hippel-Lindau Disease/diagnosis , von Hippel-Lindau Disease/psychology , Adjustment Disorders/diagnosis , Adjustment Disorders/epidemiology , Adult , Aged , Anxiety Disorders/diagnosis , Anxiety Disorders/epidemiology , Cross-Sectional Studies , Depressive Disorder/epidemiology , Depressive Disorder/psychology , Female , Genetic Predisposition to Disease/genetics , Humans , Li-Fraumeni Syndrome/genetics , Male , Middle Aged , Surveys and Questionnaires , Young Adult , von Hippel-Lindau Disease/genetics
4.
Colorectal Dis ; 13(6): 669-77, 2011 Jun.
Article in English | MEDLINE | ID: mdl-20402739

ABSTRACT

AIM: The study aimed to document the impact of familial adenomatous polyposis (FAP) on health-related quality of life (HRQOL) and several practical aspects of daily life, and to identify factors significantly associated with HRQOL. This study is the first to compare HRQOL between patients with FAP, at-risk individuals and noncarriers. METHOD: A total of 525 individuals (response rate 64%) from 145 families at high risk for FAP completed a battery of self-report questionnaires assessing generic- and condition-specific HRQOL and the consequences of FAP for daily life. RESULTS: HRQOL was comparable to that of the general Dutch population. Surgically treated patients with FAP had significantly lower scores on several HRQOL domains compared with at-risk individuals, noncarriers and nonsurgically treated patients with FAP. Type of surgery was not significantly associated with HRQOL. Within the surgically treated group, postsurgical complications and comorbidity significantly affected HRQOL. Forty-one percent of patients reported that FAP had affected their working life. CONCLUSION: Surgically treated patients with FAP have significantly poorer HRQOL than other groups. The type of surgery and age at time of first surgery were not associated with HRQOL but surgical complications and comorbidity were. Patients should be informed of the consequences of FAP for work and other life domains.


Subject(s)
Adenomatous Polyposis Coli/psychology , Quality of Life/psychology , Activities of Daily Living , Adenomatous Polyposis Coli/genetics , Adenomatous Polyposis Coli/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Body Image , Defecation , Family Health , Female , Heterozygote , Humans , Linear Models , Male , Middle Aged , Self Report , Surveys and Questionnaires , Young Adult
5.
Clin Genet ; 77(5): 483-91, 2010 May.
Article in English | MEDLINE | ID: mdl-20184621

ABSTRACT

Von Hippel-Lindau disease (VHL) is a hereditary tumor susceptibility syndrome, characterized by an increased risk of developing multiple benign and malignant tumors at various sites and ages with limited preventive options. This study evaluates the prevalence of distress among VHL family members and factors associated significantly with such distress. Forty-eight families with a VHL mutation were identified via the nine family cancer clinics in the Netherlands. In total, 171 family members (carriers, 50% at-risk, non-carriers) were approached, of whom 123 (72%) completed a self-report questionnaire. Approximately 40% of the VHL family members reported clinically relevant levels of distress, approaching 50% among the carriers and, possibly even more striking, 36% among the non-carriers. Having lost a first degree relative due to VHL during adolescence (OR 11.2; 95% CI 1.4-86.9) was related significantly to heightened levels of distress. Approximately, only one-third of those who reported heightened levels of distress had received professional psychosocial support. A substantial percentage of family members experience clinically relevant levels of distress. We would recommend the introduction of a procedure for screening for distress in this vulnerable population. Special attention should be paid to those individuals who have lost a close relative due to VHL during adolescence.


Subject(s)
von Hippel-Lindau Disease/psychology , Adult , Female , Humans , Logistic Models , Male , Quality of Life , Social Support , Surveys and Questionnaires
6.
Arch Dis Child ; 95(1): 20-5, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19679573

ABSTRACT

SETTING: Previously, treatment and the results of treatment for childhood acute lymphoblastic leukaemia (ALL) in Indonesia differed significantly between poor and prosperous patients. Poor patients received less individual attention from oncologists and access to parental education and donated chemotherapy was lacking. INTERVENTION: A structured parental education programme for both poor and prosperous parents was introduced in January 2004 to improve access to parental education and donated chemotherapy. The programme consisted of a video presentation, an information booklet, DVD, audiocassette, a statement-of-understanding for donated chemotherapy, and a complaints procedure. Informed consent was also sought. OBJECTIVE: Our study compared childhood ALL treatment outcome before and after the introduction of the parental education programme. DESIGN: The medical records of 283 children with ALL diagnosed before (1997-2002; n = 164) and after (2004-2006; n = 119) the introduction of the education programme were reviewed. Data on treatment results and parental socioeconomic status were collected. RESULTS: After the introduction of the education programme, treatment refusal decreased (from 14% to 2%) and event-free survival increased (from 13% to 29%) significantly among poor patients. Treatment dropout increased (from 0% to 13%) significantly among prosperous patients. Overall, toxic death (from 23% to 36%) increased significantly, but there was no significant difference in event-free survival. CONCLUSIONS: After introduction of the programme, treatment refusal decreased and event-free survival increased significantly among poor families. However, improved knowledge, skills and communication are still required to combat the high rates of toxic death and treatment dropout. Treatment intensity should be accompanied by improved supportive care.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Health Education/organization & administration , Parents/education , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Child , Child, Preschool , Developing Countries , Female , Health Education/methods , Health Services Accessibility/statistics & numerical data , Humans , Indonesia , Infant , Infant, Newborn , Male , Patient Dropouts/statistics & numerical data , Program Evaluation , Social Class , Socioeconomic Factors , Survival Analysis , Treatment Outcome , Treatment Refusal/statistics & numerical data
7.
Colorectal Dis ; 12(12): 1198-207, 2010 Dec.
Article in English | MEDLINE | ID: mdl-19604286

ABSTRACT

AIM: The study assessed compliance of patients with familial adenomatous polyposis (FAP) with endoscopic surveillance. METHOD: In this nationwide, cross-sectional study, individuals from FAP families registered with the Netherlands Foundation for the Detection of Hereditary Tumours were invited to complete a questionnaire on endoscopic screening experiences. RESULTS: A total of 328 individuals were eligible for the study of whom 85 were at risk for FAP, 108 had an intact rectum after a colectomy with ileorectal anastomosis (IRA), and 135 had had a pouch following a proctocolectomy with ileoanal anastomosis (IPAA). Based on medical record data, 20% of the at-risk group and 26% of the IRA-group were found to be undercompliant with surveillance advice which was associated significantly with perceived self-efficacy, use of sedatives during surveillance, pain after surveillance and low perceived benefits of surveillance (P < 0.05). CONCLUSION: One in five individuals at risk for FAP and one in four with a retained rectum are undercompliant with screening advice. We recommend that sedatives should be patient-tailored for FAP individuals undergoing surveillance and that adequate pain medication be provided after endoscopy.


Subject(s)
Adenomatous Polyposis Coli/psychology , Colorectal Neoplasms/prevention & control , Patient Compliance , Adenomatous Polyposis Coli/surgery , Adult , Colectomy , Colonoscopy , Colorectal Neoplasms/diagnosis , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Netherlands , Self Efficacy , Socioeconomic Factors , Surveys and Questionnaires
8.
Crit Rev Oncol Hematol ; 76(2): 133-41, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20036141

ABSTRACT

PURPOSE: This study aimed to identify medical and psychological predictors for cognitive performance of breast cancer (BC) patients before the start of adjuvant systemic treatment and to compare cognitive performance between BC patients and healthy controls adjusting for medical and psychological variables. MATERIAL: 205 postmenopausal BC patients underwent pre-treatment neuropsychological tests and provided medical and psychological data. 124 healthy controls underwent the same assessment. RESULTS: 'Treatment for diabetes mellitus' and/or 'hypertension', 'less hours spent on cognitively stimulating activities', 'fewer days since surgery' and 'more reproductive years' were associated with worse cognitive performance in the BC patients, independent of age and IQ. Cognitive differences between BC patients and healthy controls could partly be explained by the evaluated variables. CONCLUSION: The results stress the need for adjustment for pre-treatment cognitive differences between study groups, and also indicate that further research into pre-treatment cognitive dysfunction is warranted.


Subject(s)
Antineoplastic Agents/adverse effects , Breast Neoplasms/drug therapy , Breast Neoplasms/psychology , Cognition Disorders/epidemiology , Cognition/drug effects , Aged , Aged, 80 and over , Androstadienes/adverse effects , Breast Neoplasms/epidemiology , Chemotherapy, Adjuvant/adverse effects , Chemotherapy, Adjuvant/psychology , Cognition Disorders/chemically induced , Comorbidity , Diabetes Mellitus/epidemiology , Diabetes Mellitus/psychology , Female , Humans , Hypertension/epidemiology , Hypertension/psychology , Intelligence Tests , Middle Aged , Multicenter Studies as Topic , Neuropsychological Tests , Postmenopause , Randomized Controlled Trials as Topic , Risk Factors , Tamoxifen/adverse effects
9.
Eur J Cancer ; 45(1): 119-26, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18930387

ABSTRACT

To evaluate the association between systemic treatments and post-diagnosis weight gain in breast cancer patients during longer follow-up periods, we conducted a retrospective cohort study (n=271). Information on adjuvant systemic treatments and repeated body weight measurements was obtained from medical records, and analysed using multi-level regressions. During the first year, a mean weight change of +2.0kg (SD 4.9) was observed. Overall, 29% of all breast cancer patients had gained 5kg or more in body weight during total follow-up (median: 3 years). In multi-level analyses, women who received combined systemic treatment gained significantly more weight as compared with women who received no systemic treatment (4.5kg versus 2.0kg at 5 years post-diagnosis, p<0.05). Significant weight gain occurs in breast cancer patients in the Netherlands during the first year post-diagnosis. After the first year, further weight gain mainly occurs in women who receive chemotherapy in combination with endocrine therapy.


Subject(s)
Breast Neoplasms/therapy , Survivors , Weight Gain , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Estrogen Antagonists/therapeutic use , Female , Follow-Up Studies , Humans , Menopause , Middle Aged , Netherlands , Retrospective Studies
10.
Int J Geriatr Psychiatry ; 22(12): 1194-200, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17407168

ABSTRACT

OBJECTIVE: This study investigates the effects of benzodiazepine (BZ) use on cognitive performance in elderly persons in a longitudinal design. STUDY DESIGN AND SETTING: Data were obtained from the Longitudinal Aging Study Amsterdam (LASA), in the Netherlands. 2,105 respondents (>/=62 years of age) were included and had repeated measurements over a period of 9 years. For all BZs the type, dosage, frequency and duration of use was measured. The equivalent of a dose of diazepam was determined with regard to type and dosage and a cumulative dosage was calculated. General cognitive functioning was measured with the Mini-Mental State Examination, information processing speed was measured with the coding task, fluid intelligence with Raven's Coloured Progressive Matrices and episodic memory with the Auditory Verbal Learning Test. Multilevel analyses were used to investigate the relationship between BZ use and cognitive decline. RESULTS: A negative effect of BZ use on cognitive performance was found. However, the effect sizes were very small. CONCLUSION: This study suggests that both duration and cumulative exposure to BZ has a small negative effect on the long-term cognitive functioning of elderly people in the community.


Subject(s)
Anti-Anxiety Agents/pharmacology , Benzodiazepines/pharmacology , Cognition/drug effects , Memory/drug effects , Aged , Aged, 80 and over , Aging , Anti-Anxiety Agents/administration & dosage , Benzodiazepines/administration & dosage , Dose-Response Relationship, Drug , Female , Humans , Longitudinal Studies , Male , Middle Aged , Netherlands , Neuropsychological Tests
11.
Cancer Invest ; 24(6): 562-6, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16982459

ABSTRACT

Absorption of a physiological dose of ferrous iron was studied in 18 patients with solid malignancy receiving epoetin therapy for mild chemotherapy-associated anemia. The historical control group consisted of 25 iron replete volunteers (iron absorption 20 +/- 11% in males and 26 +/- 13% in females) and 21 patients with uncomplicated iron deficiency (iron absorption 71 +/- 19%). Iron absorption was increased in the majority of the cancer patients (iron absorption 59 +/- 35%). There were no significant differences in iron absorption between cancer patients who were iron replete or iron deficient according to current clinical practice guidelines (iron deficiency: transferrin saturation < 20% and/or serum ferritin < 100 ng/mL). Red cell iron incorporation was not disturbed in the majority (89%) of patients.


Subject(s)
Anemia/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Erythropoietin/therapeutic use , Hematinics/therapeutic use , Intestinal Absorption , Iron/metabolism , Neoplasms/metabolism , Adult , Aged , Anemia/chemically induced , Anemia/metabolism , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Epoetin Alfa , Female , Hemoglobins/metabolism , Humans , Male , Middle Aged , Neoplasms/drug therapy , Organoplatinum Compounds/administration & dosage , Recombinant Proteins
12.
Article in English | MEDLINE | ID: mdl-9829299

ABSTRACT

1. The present study compared the effects of acute intrastriatal administration of quinolinic acid (QA) and 3-nitropropionic acid (3-NP), two neurotoxins used in animal models of Huntington's disease (HD), on the following behavioral and histological measures: (1) open field activity levels; (2) performance on balance beam and grip strength tasks; (3) acquisition of a radial-arm-water-maze (RAWM) task; (4) size of striatum and lateral ventricles; (5) amount of cytochrome oxidase (CYO) labeling; and (6) counts of Nissl-stained neurons and NADPH-diaphorase-labeled neurons in the striatum. 2. Rats were given bilateral intrastriatal injections of either 200 nmol QA, 750 nmol 3-NP, or phosphate buffered saline (PBS) two weeks prior to behavioral testing and four weeks prior to histological processing. 3. The behavioral results indicated that both QA and 3-NP injections caused an increase in activity levels at two weeks postlesion, but only the QA rats showed hyperactivity at four weeks postlesion. Both QA and 3-NP rats showed significant impairment in the balance beam task, but only 3-NP rats differed significantly on the grip-strength task. Both toxins caused learning impairments in the RAWM task, with 3-NP rats being more severely impaired. 4. The neuroanatomical results indicated that both QA and 3-NP produced significant striatal atrophy and ventricular dilation, as well as a reduction in CYO staining and loss of Nissl-stained neurons, but only the 3-NP lesions created necrotic cavities in the striatum. However, the QA treatments resulted in significant loss of NADPH-diaphorase neurons in regions peripheral to the site of injection. 5. In general, these results suggest that QA treatments produce milder behavioral and neuroanatomical effects that mimic some of the earlier symptoms of HD, while 3-NP produced more severe effects which mimic both the later symptoms and the juvenile onset of HD.


Subject(s)
Corpus Striatum/drug effects , Huntington Disease/physiopathology , Huntington Disease/psychology , Maze Learning , Motor Activity , Neurotoxins/toxicity , Propionates/toxicity , Quinolinic Acid/toxicity , Animals , Cerebral Ventricles/drug effects , Cerebral Ventricles/pathology , Corpus Striatum/pathology , Corpus Striatum/physiopathology , Disease Models, Animal , Electron Transport Complex IV/metabolism , Huntington Disease/chemically induced , Male , Maze Learning/drug effects , Microinjections , Motor Activity/drug effects , Neurons/drug effects , Neurons/physiology , Neurotoxins/administration & dosage , Nitro Compounds , Propionates/administration & dosage , Quinolinic Acid/administration & dosage , Rats , Rats, Sprague-Dawley , Space Perception
13.
Oncology ; 47(1): 92-4, 1990.
Article in English | MEDLINE | ID: mdl-2300393

ABSTRACT

A coincidentally occurring papillary cancer of the thyroid in two sisters is discussed. No clinical, biochemical or chromosomal changes were found in these cases which could have shown any inheritable feature. It is concluded that, in contrast with the previous data, the simultaneous manifestation is not a peculiar feature but a fortuitous appearance.


Subject(s)
Carcinoma, Papillary/genetics , Thyroid Neoplasms/genetics , Adult , Carcinoma, Papillary/pathology , Female , Humans , Middle Aged , Thyroid Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...